Japanese pharmaceutical company Eisai is set to open a new exploratory research facility in Cambridge, Massachusetts, US, to identify new drugs for the treatment of dementia.

The Eisai Center for Genetics Guided Dementia Discovery (G2D2) will primarily work on an immuno-dementia drug discovery approach with focus on regulating neural inflammation, a primary cause of the disease.

G2D2 will build its research on human genetics, neuro- and immune-biology, and precision chemistry discerned by the Andover innovative Medicines (AiM) Institute situated in Massachusetts.

The new facility intends to carry out functional genetic analysis of dementia and focus on different proteins that are expressed on microglia as targets for drug discovery. The partners hope to introduce a compound discovered via the immuno-dementia research into the clinic by 2020.

Eisai plans to begin operations at G2D2 during the first quarter of its fiscal 2019 with around 70 employees. The centre will be led by AiM Institute president Nadeem Sarwar and that institute will be closed after the new facility becomes operational.

The company also plans to set up a research space at G2D2 that will open to external organisations and outstanding researchers.

Furthermore, Eisai hopes to advance drug discovery through G2D2’s focus on human genetics along with the European Knowledge Center in the UK run for open innovation drug discovery via partnerships with local academia, and KAN Research Institute (Kobe) working on synapse micro-environment.

The pharmaceutical firm is also accelerating organic partnership with the Eisai-Keio Innovation Lab for Dementia to carry out exploratory research for treatments using a multi-dimensional, comprehensive technique.